Literature DB >> 18816487

Determination of bergenin in human plasma after oral administration by HPLC-MS/MS method and its pharmacokinetic study.

Jin Wang1, Ben-Jie Wang, Chun-Min Wei, Gui-Yan Yuan, Rui Zhang, Hui Liu, Xiu-Mei Zhang, Rui-Chen Guo.   

Abstract

A highly sensitive, simple and selective high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method was developed and applied to the determination of bergenin concentration in human plasma. Bergenin and the internal standard (IS) thiamphenicol in plasma were extracted with ethyl acetate, separated on a C(18 )reversed-phase column, eluted with mobile phase of acetonitrile-water, ionized by negative ion pneumatically assisted electrospray and detected in the multi-reaction monitoring mode using precursor --> product ions of m/z 327.1 --> 192 for bergenin and 354 --> 185.1 for the IS, respectively. The linear range of the calibration curve for bergenin was 0.25-60 ng mL(-1), with the lowest limit of quantification of 0.25 ng mL(-1), and the intra/inter-day relative standard deviation (RSD) was less than 10%. The method is suitable for the determination of low bergenin concentration in human plasma after therapeutic oral doses, and has been first and successfully used for its pharmacokinetic studies in healthy Chinese volunteers. Copyright (c) 2008 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18816487     DOI: 10.1002/bmc.1106

Source DB:  PubMed          Journal:  Biomed Chromatogr        ISSN: 0269-3879            Impact factor:   1.902


  2 in total

1.  LC-MS/MS determination and pharmacokinetic study of bergenin, the main bioactive component of Bergenia purpurascens after oral administration in rats.

Authors:  Bao-Hong Li; Jin-Dong Wu; Xiang-Lu Li
Journal:  J Pharm Anal       Date:  2013-01-24

2.  Development and validation of UPLC-PDA method for concurrent analysis of bergenin and menisdaurin in aerial parts of Flueggea virosa (Roxb. ex Willd.).

Authors:  Afzal Hussain; Perwez Alam; Nasir Ali Siddiqui; Mohamed Fahad Alajmi; Md Tabish Rehman; Mohd Abul Kalam; Adnan Jathlan Al-Rehaily
Journal:  Saudi Pharm J       Date:  2018-05-22       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.